Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab plus chemotherapy as neoadjuvant therapy for high-risk early triple-negative breast cancer
ChiCTR2500102974Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in triple-negative breast cancer (TNBC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Total pathologic complete response. Planned start May 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2500102974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102974.